Intellia Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
CEOJohn M. Leonard
CEOJohn M. Leonard
Employees403
Employees403
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees403
Employees403
NTLA Key Statistics
Market cap1.15B
Market cap1.15B
Price-Earnings ratio-2.34
Price-Earnings ratio-2.34
Dividend yield—
Dividend yield—
Average volume4.93M
Average volume4.93M
High today$11.25
High today$11.25
Low today$10.70
Low today$10.70
Open price$11.00
Open price$11.00
Volume3.75M
Volume3.75M
52 Week high$24.16
52 Week high$24.16
52 Week low$5.90
52 Week low$5.90
NTLA News
TipRanks 3d
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game ChangerRegeneron Pharmaceuticals ((REGN)), Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: T...
TipRanks 4d
Regeneron and Intellia’s Phase 3 Study on NTLA-2001: A Potential Game-Changer for ATTRv-PNRegeneron Pharmaceuticals ((REGN)), Intellia Therapeutics Inc ((NTLA)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: T...
Analyst ratings
75%
of 28 ratingsBuy
75%
Hold
21.4%
Sell
3.6%
People also own
Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.